Trastuzumab-QYYP - Save Up to 90% with Coupons, Discounts & Assistance Programs

Trastuzumab-QYYP is available as a 150 mg or 420 mg IV injection.

Trastuzumab-QYYP is a monoclonal antibody that is used to treat:
HER2-positive, breast cancers – IV and SQ injections
HER2-positive, metastatic stomach cancer – IV injection only

Trastuzumab-QYYP s a monoclonal antibody that acts as a human epidermal growth factor receptor 2 (HER2) inhibitor. It blocks a specific protein in the body that’s important for cell growth called HER2. HER2 is found on both normal and cancer cells. Cancer cells usually have more HER2 proteins than normal cells. This can cause cancer cells to grow more quickly than normal cells. When HER2 is blocked by Trastuzumab-QYYP, cancer cells can’t grow and spread as well.

Trastuzumab-QYYP is given by a healthcare provider as an injection into a vein (IV).

When given IV, the dose depends on your body weight. Your healthcare provider will determine the appropriate dose for you each time you receive the medication.

HER2-positive, breast cancers

IV injection: The typical dose is 4 mg/kg of bodyweight IV for the first injection, and then 2 mg/kg given once a week. It can also be given as 8 mg/kg for the first injection, and then 6 mg/kg every 3 weeks thereafter.

HER2-positive, metastatic stomach cancer: The typical dose is 8 mg/kg IV for the first injection, and then 6 mg/kg every 3 weeks thereafter.

Trastuzumab-QYYP is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Trastuzumab-QYYP:

• Body and joint pain
• Weakness
• Fever
• Nausea
• Chills
• Headache
• Cough
• Diarrhea
• Vomiting
• Infection

Serious side effects are rare with Trastuzumab-QYYP. Contact your healthcare provider immediately if you experience any of the following.
Heart problems: chest pain, racing heartbeat, shortness of breath that usually worsens with activity or while lying flat, swelling of your legs or feet, sudden weight gain, fatigue
Serious infusion reactions: trouble breathing, itching or hives, flushing, swelling, chest pain, fast heartbeat, dizziness, fainting
Lung problems: shortness of breath, trouble breathing
Serious infections (when receiving in combination with chemotherapy): repeated fevers, chills, sweating, cough, trouble breathing, severe diarrhea, vomiting, painful or frequent urination

The following medications may interact with Trastuzumab-QYYP:

• Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab’s long washout period based on population PK analysis. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, the patient’s cardiac function should be monitored carefully.

Various FDA-approved generic manufacturers

Trastuzumab-QYYP can cause fetal harm when administered to a pregnant woman. If you can become pregnant, you should use effective contraception during treatment with Trastuzumab-QYYP and for 7 months following the last dose of Trastuzumab-QYYP. Contact your doctor immediately if you become pregnant while taking this medication.

• Trazimera